Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2021 08:00 ET | Source: Active Biotech

Active Biotechs partner NeoTX presenterar vid det årliga mötet i Society for Immunotherapy of Cancer (SITC)

Lund, November 9, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och samarbetspartnern NeoTX meddelar idag att naptumomab estafenatox (naptumomab, NAP) kommer att presenteras på The Society för...
November 09, 2021 08:00 ET | Source: Active Biotech

Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lund, November 9, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today a presentation on naptumomab estafenatox (naptumomab, NAP), at the Society for Immunotherapy of...
November 04, 2021 09:00 ET | Source: Active Biotech

Nya prekliniska data kring tasquinimod kommer att presenteras på det årliga mötet i American Society of Hematology (ASH)

Lund, 4 november 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelade idag att två abstrakt med nya prekliniska data kring tasquinimod, en småmolekylar immunmodulator, har blivit accepterade för...
November 04, 2021 09:00 ET | Source: Active Biotech

New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for...
November 04, 2021 03:30 ET | Source: Active Biotech

Active Biotech Delårsrapport januari - september 2021

”Vi har fått de första uppmuntrande resultaten från den pågående tasquinimod-studien i multipelt myelom och startat en ny kombinationsstudie med naptumomab och docetaxel i lungcancer” TREDJE...
November 04, 2021 03:30 ET | Source: Active Biotech

Active Biotech Interim report January - September 2021

“We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer” THIRD...
October 20, 2021 01:00 ET | Source: Active Biotech

Active Biotech och NeoTX meddelar idag att den första patienten har rekryterats i den kliniska fas IIa-studien med naptumomab estafenatox i kombination med docetaxel i patienter med lungcancer

Lund, 20 Oktober 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och dess samarbetspartner NeoTX meddelar idag att den första patienten har rekryterats i den kliniska fas IIa-studien med naptumomab...
October 20, 2021 01:00 ET | Source: Active Biotech

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

Lund, October 20, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox...
October 03, 2021 15:30 ET | Source: Active Biotech

Active Biotech: Utvecklingen av tasquinimod i multipelt myelom fortsätter i kombinationsbehandling efter att den inledande fasen av den pågående studien i USA slutförts

Lund, 3 oktober 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar idag att den pågående kliniska studien med tasquinimod i multipelt myelom har nått en viktig milstolpe. Tio patienter har...
October 03, 2021 15:30 ET | Source: Active Biotech

Active Biotech: Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Lund Sweden, October 3, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have...